The evidence yielded by the PARADIGM-HF trial, and the clinical experience in the Middle East (the Gulf region in particular) indicates that sacubitril/valsartan is associated with reduced short-term mortality and hospitalization rates in CHF patients irrespective of ACE inhibitor administration in target doses [2, 3]. The gene discussed is ACE; the disease is hydrops fetalis.